Who to call at Vistagen Therapeutics, Inc., and when
Fundz watches for the moments Vistagen Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Vistagen Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Vistagen Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Vistagen Therapeutics, Inc.. With Fundz connected, it knows.
Vistagen Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.vistagen.comAI Executive Summary
AI-powered analysis of 8-K filing content
Vistagen Therapeutics appointed Paul R. Edick as a director on October 27, 2025, placing him on the Audit and Compensation Committees with options to purchase 35,200 shares at $3.90 per share. This is a routine governance addition with no stated operational or financial change.
Key Takeaways
Paul R. Edick joined the Board on October 27, 2025, on the recommendation of the Corporate Governance and Nominating Committee, and the Board approved the appointment unanimously.
Edick serves on both the Audit Committee and the Compensation Committee, which places a new independent-minded director in oversight of financial reporting and executive pay.
3 more takeaways
Related Filings (20)
20 more filings from Vistagen Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Vistagen Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.